Trials / Completed
CompletedNCT07370220
Effect of Rutin on Inflammation Pathways in Ulcerative Colitis Patients
Rutin Therapy Reduces Ulcerative Colitis Disease Activity By Inhibiting The NOD-Like Receptor Protein 3 (NLRP3) Inflammasome: A Molecular Assessment in an Interventional Study.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Benha University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the therapeutic role of Rutin (a plant-derived flavonoid) in reducing the severity of Ulcerative Colitis (UC). The study investigates whether Rutin can decrease intestinal inflammation and improve clinical symptoms by inhibiting the NLRP3 inflammasome signaling pathway, which is activated by oxidative stress in the colon.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rutin 500 MG Oral Tablet | Oral capsules twice daily for 30 days |
| DIAGNOSTIC_TEST | Fecal Calprotectin | Sample collection only for baseline comparison. |
| DRUG | Placebo | Placebo tablets for 30 days |
Timeline
- Start date
- 2025-02-22
- Primary completion
- 2025-05-25
- Completion
- 2025-11-15
- First posted
- 2026-01-27
- Last updated
- 2026-01-27
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT07370220. Inclusion in this directory is not an endorsement.